Condition: Multiple Myeloma · Sponsor: University of California, San Diego
This study evaluates the efficacy of elranatamab alone in patients with relapsed and/or refractory Multiple myeloma who has previously received 1 to 3 combinations of treatment.
This description comes directly from the study's public registry record.
Ah-Reum Jeong · (858) 822-6600 · ajeong@health.ucsd.edu
Bone Marrow Transplant Research Team · (858) 822-5354 · CancerCTO@health.ucsd.edu
Always discuss trial participation with your own doctor first.
| University of California San Diego | La Jolla, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06711705